Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Eukaryotic Gene Expression
IF: 2.156 5-Year IF: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Print: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v26.i1.30
pages 19-26

The Importance of Mutational Drivers in GBM

Rasime Kalkan
Near East University, Faculty of Medicine, Department of Medical Genetics, Cyprus


Glioblastoma (GBM) is the most aggressive primary brain tumor, providing few effective therapeutic options, given the tumor heterogeneity and the accumulation of different genetic abnormalities that cause treatment failure. The many different genetic and epigenetic alterations present in GBM lead to modification of several major signaling pathways resulting in brain tumor growth, progression, and therapeutic resistance. Many functionally important mutations have been discovered, known as neutral passengers. IDH1/2, EZH2, and DNMT3A are the best known epigenetic modifiers in cancer. These mutations are important in determining disease prognosis such that the status of the MGMT gene is a direct target of chemotherapy. For these reasons, newly developed technologies are necessary to determine new candidate targets for targeted-therapy development in GBM. The determination of mutations will aid in this and in the discovery of combinations of targeted and conventional therapies to improve GBM treatment.

KEY WORDS: mutation, IDH1, driver, GBM

Articles with similar content:

The Impacts of miRNAs in Glioblastoma Progression
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 2
Rasime Kalkan, Emine İkbal Atli
Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan
From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Genetic and Epigenetic Control of RKIP Transcription
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Milad S. Bitar, Kevin Qin, Kam C. Yeung, Fahd Al-Mulla, Hanna Tegegne, Ila Datar, Robert J. Trumbly
Targeting the Human Kinome for Cancer Therapy: Current Perspectives
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Luxi Zhang , Roger J. Daly